Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZYNE Stock Summary
- Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.07% of US listed stocks.
- With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set.
- The volatility of Zynerba Pharmaceuticals Inc's share price is greater than that of 93.47% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Zynerba Pharmaceuticals Inc, a group of peers worth examining would be BPMX, RVNC, ADVM, PSTI, and PRTA.
- Visit ZYNE's SEC page to see the company's official filings. To visit the company's web site, go to www.zynerba.com.
ZYNE Stock Price Chart Interactive Chart >
ZYNE Price/Volume Stats
| Current price | $5.49 | 52-week high | $9.00 |
| Prev. close | $5.58 | 52-week low | $3.12 |
| Day low | $5.45 | Volume | 221,275 |
| Day high | $5.62 | Avg. volume | 3,684,771 |
| 50-day MA | $4.72 | Dividend yield | N/A |
| 200-day MA | $4.24 | Market Cap | 226.47M |
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio
Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.
Latest ZYNE News From Around the Web
Below are the latest news stories about Zynerba Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.
Zynerba's Zygel Improves Sleep In Children With Severe EpilepsiesZynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting. The treatment was associated with improved sleep in children with clinically significant sleep disorders at baseline. Furthermore, the children with both DEE and autism spectrum disorder (ASD) showed m |
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual MeetingDEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC. A copy of the poster is available on the Zynerba corporate website at http://zynerba.com/publications/. The poster titled “Impact of ZYN002 Cannabidiol Tra |
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting– 46.4% of shares voted, quorum not established to hold annual meeting – – Meeting scheduled to reconvene June 29, 2021 at 9:00 AM EDT – – Company strongly encourages stockholders holding unvoted proxies to cast their votes – DEVON, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that it has adjourned its 2021 |
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Zynerba Pharmaceuticals, Inc. – ZYNEPHILADELPHIA, June 07, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP and The Rosen Law Firm, P.A. announces that the United States District Court for the Eastern District of Pennsylvania has approved the following announcement of a proposed class action settlement that would benefit purchasers of securities of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION AND FINAL APPROVAL HEARING TO: ALL PERSONS WHO PURCHASED OR OTHERWISE ACQUIRED SEC |
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual MeetingDEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at SLEEP 2021, the 35th Annual Meeting of the Associated Professional Sleep Societies, LLC, which will be held virtually from June 10-13, 2021. A copy of the poster will be made available on the Zynerba c |
ZYNE Price Returns
| 1-mo | 21.73% |
| 3-mo | 3.39% |
| 6-mo | 61.47% |
| 1-year | -14.62% |
| 3-year | -49.49% |
| 5-year | -27.28% |
| YTD | 66.36% |
| 2020 | -45.36% |
| 2019 | 103.37% |
| 2018 | -76.28% |
| 2017 | -19.69% |
| 2016 | 54.82% |
Continue Researching ZYNE
Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...